BDC-1001, PERTUZUMAB
BBI-20231001
Phase 2 small_molecule active
Quick answer
BDC-1001, PERTUZUMAB for HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER is a Phase 2 program (small_molecule) at Bolt Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bolt Biotherapeutics
- Indication
- HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active